In an effort to help seniors impacted by the "doughnut hole," Shire Pharmaceuticals is launching a new Medicare Part D component under the Fosrenol (lanthanum carbonate) At Hand Patient Assistance Program.
Shire provides help to patients who have no coverage for Fosrenol under prescription drug benefits, Medicare, Medicaid, or other state-funded programs, by providing the drug free of charge or at a shared (reduced) cost. Now, qualifying patients enrolled in a Medicare Part D program who cannot afford their copayments or coinsurance, along with those facing the doughnut-hole coverage gap, may receive the drug at no cost. Patients will receive a monthly supply of Fosrenol through the end of the calendar year in which they enroll in the program.
Fosrenol is indicated to reduce serum phosphate in patients with end-stage renal disease. For more information about the program, call 866-325-8223.
One study linked multiple pregnancies to an increased risk of developing atrial fibrillation later in life, and another investigated the association between premature delivery and cardiovascular disease.
Clinical features with downloadable PDFs